Continuation of Research and Development Activities
First written in FY2017-Q1. 1 of 35 entries say "Restated". Latest entry: FY2026.
47 other companies' latest entry also says "Other".
- FY2026Increase in full-year R&D expensesAnnual report
「The main R&D activities by segment are as follows, and total R&D expenditure for the fiscal year was ¥1,073 million.」
R&D into new technologies, materials and products continued, and R&D expenditure increased from ¥1,052 million in the previous fiscal year to ¥1,073 million. - FY2026-H1Decline in first-half R&D expensesAnnual report
「Group-wide R&D expenditure for the six-month interim consolidated accounting period was ¥545 million.」
Although it states that there were no material changes in its R&D activities, R&D expenditure decreased from ¥549 million in the same period of the previous year to ¥545 million. - FY2025Decrease in full-year R&D expensesAnnual report
「Total R&D expenditure for the fiscal year was ¥1,052 million.」
Although R&D activities continued and the development of new technologies, materials and products progressed, R&D expenditure decreased from ¥1,065 million in the previous fiscal year to ¥1,052 million. - FY2025-H1Increase in second-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the six-month interim consolidated accounting period was ¥549 million.」
Although it states that there were no material changes in the status of its R&D activities, R&D expenditure increased from ¥513 million in the same period of the previous year to ¥549 million. - FY2024-Q3Increase in third-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥815 million.」
R&D expenditure for the nine months ended the third quarter was ¥815 million, up from ¥762 million in the same period of the previous year. The company states that there were no material changes in the status of its R&D activities. - FY2024-Q2Increase in second-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥552 million.」
R&D expenditure for the six months ended the second quarter was ¥552 million, up from ¥507 million in the same period of the previous year. The company states that there were no material changes in the status of its R&D activities. - FY2024-Q1Increase in first-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥272 million.」
Although it states that there were no material changes in the status of its R&D activities, R&D expenditure increased from ¥255 million in the same period of the previous year to ¥272 million. - FY2023Decrease in full-year R&D expensesAnnual report
「Total R&D expenditure for the fiscal year was ¥1,065 million.」
Although R&D into new technologies, materials and products continued, R&D expenditure decreased from ¥1,109 million in the previous fiscal year to ¥1,065 million. - FY2023-Q3Decline in third-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥762 million.」
Although it states that there were no material changes in the status of its R&D activities, R&D expenditure decreased from ¥835 million in the same period of the previous year to ¥762 million. - FY2023-Q2Increase in second-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥513 million.」
Although it states that there were no material changes in the status of its R&D activities, R&D expenditure increased from ¥507 million in the same period of the previous year to ¥513 million. - FY2023-Q1Decline in first-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥255 million.」
Although it states that there were no material changes in the status of its R&D activities, R&D expenditure decreased from ¥277 million in the same period of the previous year to ¥255 million. - FY2022Increase in full-year R&D expensesAnnual report
「The main R&D activities by segment are as follows, and total R&D expenditure for the fiscal year was ¥1,109 million.」
R&D activities continued, and total R&D expenditure increased from ¥900 million in the previous fiscal year to ¥1,109 million. - FY2022-Q3Disclosure of third-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥835 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure of ¥835 million for the nine months ended the third quarter was disclosed. - FY2022-Q2Increase in second-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥507 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure increased from ¥439 million in the same period of the previous year to ¥507 million. - FY2022-Q1Increase in first-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥277 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure increased from ¥207 million in the same period of the previous year to ¥277 million. - FY2021Decrease in full-year R&D expensesAnnual report
「Total R&D expenditure for the fiscal year was ¥900 million.」
Although R&D activities continued, total R&D expenditure decreased from ¥977 million in the previous fiscal year to ¥900 million. - FY2021-Q3Decline in third-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥678 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
Although it states that there were no material changes in the status of its R&D activities, R&D expenditure decreased from ¥736 million in the same period of the previous year to ¥678 million. - FY2021-Q2Decline in second-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥439 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
Although it states that there were no material changes in the status of its R&D activities, R&D expenditure decreased from ¥488 million in the same period of the previous year to ¥439 million. - FY2021-Q1Decline in first-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥207 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
Although there were no material changes in the nature of its R&D activities, R&D expenditure decreased from ¥240 million in the same period of the previous year to ¥207 million. - FY2020Decrease in full-year R&D expensesAnnual report
「Total R&D expenditure for the fiscal year was ¥977 million.」
Although R&D activities continued, total R&D expenditure decreased from ¥1,120 million in the previous fiscal year to ¥977 million. - FY2020-Q3Decline in third-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥736 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure decreased from ¥846 million in the same period of the previous year to ¥736 million. - FY2020-Q2Decline in second-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥488 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure decreased from ¥570 million in the same period of the previous year to ¥488 million. - FY2020-Q1Decline in first-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥240 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
Although it states that there were no material changes in the status of its R&D activities, R&D expenditure decreased from ¥285 million in the same period of the previous year to ¥240 million. - FY2019Decrease in full-year R&D expensesAnnual report
「Total R&D expenditure for the fiscal year was ¥1,120 million.」
Although R&D into new technologies, materials and products continued, R&D expenditure decreased from ¥1,323 million in the previous fiscal year to ¥1,120 million. - FY2019-Q3Disclosure of third-quarter R&D expensesAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥846 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure of ¥846 million for the nine months ended the third quarter was disclosed. - FY2019-Q2Disclosure of second-quarter research and development expensesAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥570 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure of ¥570 million for the six months ended the second quarter was disclosed. - FY2019-Q1Decline in quarterly R&D expensesAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥285 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure decreased from ¥348 million in the same period of the previous year to ¥285 million. - FY2018Decrease in full-year R&D expensesAnnual report
「Total R&D expenditure for the fiscal year was ¥1,323 million.」
Although R&D into new technologies, materials and products continued, total R&D expenditure decreased from ¥1,392 million in the previous fiscal year to ¥1,323 million. - FY2018-Q3Increase in R&D expensesAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥1,002 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure increased from ¥678 million for the six months ended the second quarter to ¥1,002 million. - FY2018-Q2Increase in R&D expensesAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥678 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure increased from ¥348 million for the six months ended the first quarter to ¥678 million. - FY2018-Q1RestatedAnnual report
「Group-wide R&D expenditure for the three months ended the first quarter was ¥348 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
R&D expenditure of ¥348 million was disclosed, with no material changes in the status of R&D activities reported. - FY2017Full-Year R&D Expense DisclosureAnnual report
「During the fiscal year, the Group pursued the development of new technologies and products anticipating market needs by organically combining research into new technologies and materials with its accumulated technologies, under a structure centered on the Technical Development Headquarters of the consolidated company and designed to harness the combined capabilities of its technical divisions. The main R&D activities by segment are as follows, and total R&D expenditure for the fiscal year was ¥1,392 million.」
R&D into new technologies, materials and products continued, with total full-year R&D expenditure disclosed at ¥1,392 million. - FY2017-Q3Increase in R&D expensesAnnual report
「Group-wide R&D expenditure for the nine months ended the third quarter was ¥1,060 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure increased from ¥689 million for the six months ended the previous quarter to ¥1,060 million. - FY2017-Q2Increase in R&D expensesAnnual report
「Group-wide R&D expenditure for the six months ended the second quarter was ¥689 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
Although it states that there were no material changes in the nature of its R&D activities, R&D expenditure increased from ¥349 million in the previous quarter to ¥689 million. - FY2017-Q1First statedAnnual report
「The Group’s total research and development expenditure for the first quarter of the current consolidated cumulative period was ¥349 million. There were no significant changes in the Group’s research and development activities during the first quarter of the current consolidated cumulative period.」
Quarterly research and development expenditure is disclosed, with no significant changes in research and development activities reported.